Home > News > Editor Favorites

VA faults self over Chantix test

Peake awaits review, vows accountability

By Audrey Hudson and Jen Haberkorn | Thursday, July 10, 2008

Article
Comments ()

Department of Veterans Affairs watchdogs have concluded that the department failed to alert veterans suffering from post-traumatic stress disorder in a timely manner to the dangers posed by a drug it was prescribing, VA officials acknowledged Wednesday under sharp questioning from lawmakers.

The legislators also were told that the department's inspector general has begun investigating a report that research personnel falsified certain study records at the VA Medical Center in the District.

"That is something we need to make sure never happens again," VA Secretary James B. Peake said of the delayed warnings to veterans using the smoking-cessation drug Chantix, which has been linked to psychotic and suicidal behavior in its users.

He said that veterans participating in a smoking-cessation study can continue to take the drug, but that an internal review conducted by agency doctors will have the final say in a report to Congress on July 18.

"I have dictated a detailed review not only on this study, but of all studies involving our veterans with PTSD," Mr. Peake told the House Veterans' Affairs Committee oversight hearing.

"Where we find inadequacies, I will demand institutional and personal accountability," Mr. Peake said.

A review by the VA Office of Inspector General found that researchers in the study "did not ensure that patients involved in the smoking cessation study were notified of the risk of suicidal thoughts or behavior in a timely manner."

The Food and Drug Administration issued its first alert in November that side effects of Chantix could include suicidal thoughts and behavior, and the drug company Pfizer followed with a warning label change in January. The FDA issued another alert on Feb. 5, but warning letters trickled out to study participants from March to June.

The IG said it could not confirm whether warning letters reached the intended study participants, and more than half have not signed and returned amended consent forms advising that the drug may cause hallucinations or psychotic or suicidal behavior.